Enavogliflozin

Cat. No.: HY-109144

CAS No.: 1415472-28-4

Molecular Formula: $C_{24}H_{27}ClO_6$

Molecular Weight: 446.92

Target: SGLT

Pathway: Membrane Transporter/Ion Channel

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (223.75 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2375 mL	11.1877 mL	22.3754 mL
	5 mM	0.4475 mL	2.2375 mL	4.4751 mL
	10 mM	0.2238 mL	1.1188 mL	2.2375 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.59 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.59 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.59 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].

IC_{50} & Target

SGLT2

In Vitro

Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Daewoong speeds up developing antidiabetic Enavogliflozin

[2]. These are the results of clinical trials of the diabetes drug Enavogliflozin and Metformin

[3]. Global Diabetes Pipeline Landscape Report 2020 Featuring Daewoong's Enavogliflozin & Janssen Biotech's Golimumab Among Others - ResearchAndMarkets.com

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA